Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy